Immunic Inc

NASDAQ:IMUX   3:59:55 PM EDT
16.99
-0.01 (-0.06%)
Regulatory, Earnings Announcements

Immunic, Inc. Announces Results From Interim Safety Analysis And Recruitment Update From Its Ongoing Phase 2 Calvid-1 Trial Of Imu-838 In Patients With Moderate Covid-19

Published: 09/28/2020 11:10 GMT
Immunic Inc (IMUX) - Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 Calvid-1 Trial of Imu-838 in Patients With Moderate Covid-19.
Immunic Inc - to Date, 110 Patients Have Been Enrolled in Calvid-1 Trial and Enrollment is Progressing Well.
Immunic Inc - Independent Data Monitoring Committee (idmc) Has Concluded That Study Should Continue Without Changes.
Immunic Inc - Trial is Expected to Initially Enroll About 230 Patients at 10-35 Centers Across Europe and U.S.immunic - Plan to Report Results of Pre-planned Unblinded Interim Analysis of All Available Efficacy, Biomarker and Virus Titer Data Later This Year.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.62

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.55

More details on our Analysts Page.